XERS (Xeris Biopharma Holdings) Total Receivables: $56.3 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XERS Xeris Biopharma Holdings Inc XERS
71 GF Score
Price $8.28
GF Value $5.20
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Xeris Biopharma Holdings Total Receivables?

Xeris Biopharma Holdings XERS +1.47% 71 Total Receivables is $56.3 Mil as of Mar. 2026. GuruFocus rates XERS with a GF Score™ of 71/100 and a GF Value™ of $5.20 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Xeris Biopharma Holdings's Total Receivables for the quarter that ended in Mar. 2026 was $56.3 Mil.

Xeris Biopharma Holdings Total Receivables Related Terms

Xeris Biopharma Holdings Total Receivables Historical Data

* Premium members only.

The historical data trend for Xeris Biopharma Holdings's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xeris Biopharma Holdings Total Receivables Chart

Xeris Biopharma Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 17.46 30.83 39.20 40.42 51.05

Xeris Biopharma Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.33 53.05 53.75 51.05 56.30
XERS
71GF Score
Xeris Biopharma Holdings Inc XERS
Total Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xeris Biopharma Holdings Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of $56.3 Mil mean?
Xeris Biopharma Holdings (XERS) has a Total Receivables of $56.3 Mil as of Mar. 2026. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Xeris Biopharma Holdings and its competitors.
Is Xeris Biopharma Holdings' Total Receivables too high?
Xeris Biopharma Holdings' current Total Receivables is $56.3 Mil. Overall, Xeris Biopharma Holdings has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Xeris Biopharma Holdings' Total Receivables compare to PAHC and PRGO?
Xeris Biopharma Holdings' Total Receivables of $56.3 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Drug Manufacturers company?
A good Total Receivables depends on the Drug Manufacturers industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Xeris Biopharma Holdings and its competitors. Xeris Biopharma Holdings's current Total Receivables is $56.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xeris Biopharma Holdings stock overvalued right now?
Based on GuruFocus' analysis, Xeris Biopharma Holdings (XERS) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.20, compared to a current price of $8.28 — trading 59.2% above its estimated fair value. The current Total Receivables is $56.3 Mil. Xeris Biopharma Holdings' overall GF Score™ is 71/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Xeris Biopharma Holdings (XERS), the current Total Receivables is $56.3 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xeris Biopharma Holdings (XERS) Overvalued in 2026?

Based on GuruFocus' analysis, Xeris Biopharma Holdings stock appears to be overvalued. The current stock price of $8.28 is trading 59.2% above its estimated GF Value™ of $5.20. GuruFocus considers Xeris Biopharma Holdings to be Significantly Overvalued.

Key valuation signals for XERS:

  • Total Receivables: $56.3 Mil
  • GF Value™: $5.20 vs. price of $8.28 (59.2% above fair value)
  • GF Score™: 71/100 with 6 warning signs

No single metric tells the full story. See the XERS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Xeris Biopharma Holdings Business Description

Other Exchanges 0A8E:UK2B30:Germany
Address 1375 West Fulton Street, Suite 1300, Chicago, IL, USA, 60607
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
71GF Score

Get the complete analysis for XERS

Total Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.28
Price
$5.20
GF Value